Progressive age‐related development of Alzheimer‐like pathology in APP/PS1 mice
暂无分享,去创建一个
Ottavio Arancio | O. Arancio | F. Battaglia | P. Mathews | Paul M Mathews | Fortunato Battaglia | Fabrizio Trinchese | Shumin Liu | Shumin Liu | Sean Walter | F. Trinchese | S. Walter
[1] R. Morris,et al. Place navigation impaired in rats with hippocampal lesions , 1982, Nature.
[2] D. Salmon,et al. Physical basis of cognitive alterations in alzheimer's disease: Synapse loss is the major correlate of cognitive impairment , 1991, Annals of neurology.
[3] Gary Lynch,et al. Alterations in synaptic transmission and long-term potentiation in hippocampal slices from young and aged PDAPP mice , 1999, Brain Research.
[4] P. Greengard,et al. Intraneuronal Abeta42 accumulation in human brain. , 2000, The American journal of pathology.
[5] Brian J Cummings,et al. β-amyloid deposition and other measures of neuropathology predict cognitive status in Alzheimer's disease , 1996, Neurobiology of Aging.
[6] G. Collingridge,et al. Age-Related Impairment of Synaptic Transmission But Normal Long-Term Potentiation in Transgenic Mice that Overexpress the Human APP695SWE Mutant Form of Amyloid Precursor Protein , 2001, The Journal of Neuroscience.
[7] P. Greengard,et al. Intraneuronal Aβ42 Accumulation in Human Brain , 2000 .
[8] J. Hardy,et al. Aβ peptide vaccination prevents memory loss in an animal model of Alzheimer's disease , 2000, Nature.
[9] S. Younkin,et al. Correlative Memory Deficits, Aβ Elevation, and Amyloid Plaques in Transgenic Mice , 1996, Science.
[10] B. Hyman,et al. Age-related amyloid beta deposition in transgenic mice overexpressing both Alzheimer mutant presenilin 1 and amyloid beta precursor protein Swedish mutant is not associated with global neuronal loss. , 2000, The American journal of pathology.
[11] F. Checler,et al. Immunohistochemical Analysis of Cerebral Cortical and Vascular Lesions in the Primate Microcebus murinus Reveal Distinct Amyloid β1–42 and β1–40 Immunoreactivity Profiles , 2000, Neurobiology of Disease.
[12] R. Nicoll,et al. Plaque-independent disruption of neural circuits in Alzheimer's disease mouse models. , 1999, Proceedings of the National Academy of Sciences of the United States of America.
[13] Mikio Shoji,et al. Age-Dependent Changes in Brain, CSF, and Plasma Amyloid β Protein in the Tg2576 Transgenic Mouse Model of Alzheimer's Disease , 2001, The Journal of Neuroscience.
[14] D. Linden,et al. Synaptic transmission and hippocampal long-term potentiation in olfactory cyclic nucleotide-gated channel type 1 null mouse. , 1998, Journal of neurophysiology.
[15] T. Iwatsubo,et al. Visualization of A beta 42(43) and A beta 40 in senile plaques with end-specific A beta monoclonals: evidence that an initially deposited species is A beta 42(43). , 1994, Neuron.
[16] D. Mann,et al. Diffuse Plaques in the Cerebellum and Corpus Striatum in Down's Syndrome Contain Amyloid β Protein (Aβ) only in the Form of Aβ42(43) , 1996 .
[17] E. Kandel,et al. Strain-dependent differences in LTP and hippocampus-dependent memory in inbred mice. , 2000, Learning & memory.
[18] O. Vitolo,et al. Amyloid β-peptide inhibition of the PKA/CREB pathway and long-term potentiation: Reversibility by drugs that enhance cAMP signaling , 2002, Proceedings of the National Academy of Sciences of the United States of America.
[19] D. Dickson,et al. Amyloid Phenotype Characterization of Transgenic Mice Overexpressing both Mutant Amyloid Precursor Protein and Mutant Presenilin 1 Transgenes , 1999, Neurobiology of Disease.
[20] M. Shapiro,et al. Impaired learning and LTP in mice expressing the carboxy terminus of the Alzheimer amyloid precursor protein , 1997, Nature.
[21] D. Mann,et al. Diffuse plaques in the cerebellum and corpus striatum in Down's syndrome contain amyloid beta protein (A beta) only in the form of A beta 42(43). , 1996, Neurodegeneration : a journal for neurodegenerative disorders, neuroprotection, and neuroregeneration.
[22] J. Sweatt,et al. Accelerated Plaque Accumulation, Associative Learning Deficits, and Up-regulation of α7 Nicotinic Receptor Protein in Transgenic Mice Co-expressing Mutant Human Presenilin 1 and Amyloid Precursor Proteins* , 2002, The Journal of Biological Chemistry.
[23] H. Tanila,et al. Abeta levels in serum, CSF and brain, and cognitive deficits in APP + PS1 transgenic mice. , 2003, Neuroreport.
[24] S. Qian,et al. Transgenic mice expressing the PS1-A246E mutation: effects on spatial learning, exploration, anxiety, and motor coordination , 2003, Behavioural Brain Research.
[25] D. Borchelt,et al. An Alzheimer's Disease-Linked PS1 Variant Rescues the Developmental Abnormalities of PS1-Deficient Embryos , 1998, Neuron.
[26] G. Arendash,et al. Progressive and gender-dependent cognitive impairment in the APPSW transgenic mouse model for Alzheimer’s disease , 1999, Behavioural Brain Research.
[27] N Butters,et al. Detection and staging of dementia in Alzheimer's disease. Use of the neuropsychological measures developed for the Consortium to Establish a Registry for Alzheimer's Disease. , 1992, Archives of neurology.
[28] H. Cai,et al. Genetically engineered mouse models of neurodegenerative diseases , 2002, Nature Neuroscience.
[29] M. Mattson,et al. Triple-Transgenic Model of Alzheimer's Disease with Plaques and Tangles Intracellular Aβ and Synaptic Dysfunction , 2003, Neuron.
[30] Ralph A. Nixon,et al. Aβ peptide immunization reduces behavioural impairment and plaques in a model of Alzheimer's disease , 2000, Nature.
[31] Brian J Cummings,et al. Beta-amyloid deposition and other measures of neuropathology predict cognitive status in Alzheimer's disease. , 1996, Neurobiology of aging.
[32] C. Kawas,et al. Neuronal cell death in Alzheimer's disease correlates with apoE uptake and intracellular Abeta stabilization. , 1997, The Journal of clinical investigation.
[33] N Butters,et al. Detection of abnormal memory decline in mild cases of Alzheimer's disease using CERAD neuropsychological measures. , 1991, Archives of neurology.
[34] T. Iwatsubo,et al. Association of A beta 40-positive senile plaques with microglial cells in the brains of patients with Alzheimer's disease and in non-demented aged individuals. , 1996, Neurodegeneration : a journal for neurodegenerative disorders, neuroprotection, and neuroregeneration.
[35] Gurparkash Singh,et al. Mutant Human Presenilin 1 Protects presenilin 1 Null Mouse against Embryonic Lethality and Elevates Aβ1–42/43 Expression , 1998, Neuron.
[36] K. Davis,et al. Correlation between elevated levels of amyloid beta-peptide in the brain and cognitive decline. , 2000, JAMA.
[37] G M Rose,et al. Exposing rats to a predator impairs spatial working memory in the radial arm water maze , 1999, Hippocampus.
[38] D. Davies,et al. Neurodegenerative Changes Associated with β-Amyloid Deposition in the Brains of Mice Carrying Mutant Amyloid Precursor Protein and Mutant Presenilin-1 Transgenes , 2001, Experimental Neurology.
[39] D. Mann,et al. Amyloid β protein (Aβ) deposition: Aβ42(43) precedes Aβ40 in down Syndrome , 1995, Annals of neurology.
[40] E. Masliah,et al. Mechanisms of synaptic dysfunction in Alzheimer's disease. , 1995, Histology and histopathology.
[41] P. S. St George-Hyslop,et al. A beta peptide immunization reduces behavioural impairment and plaques in a model of Alzheimer's disease. , 2000, Nature.
[42] M. Roth,et al. The Association Between Quantitative Measures of Dementia and of Senile Change in the Cerebral Grey Matter of Elderly Subjects , 1968, British Journal of Psychiatry.
[43] Stephen Maren,et al. Overexpression of hAPPswe impairs rewarded alternation and contextual fear conditioning in a transgenic mouse model of Alzheimer's disease. , 2002, Learning & memory.
[44] J. Roder,et al. Spatial learning in transgenic mice expressing human presenilin 1 (PS1) transgenes , 2000, Neurobiology of Aging.
[45] J. Hardy,et al. A beta peptide vaccination prevents memory loss in an animal model of Alzheimer's disease. , 2000, Nature.
[46] Veerle Baekelandt,et al. Early Phenotypic Changes in Transgenic Mice That Overexpress Different Mutants of Amyloid Precursor Protein in Brain* , 1999, The Journal of Biological Chemistry.
[47] J. Hardy,et al. Accelerated Alzheimer-type phenotype in transgenic mice carrying both mutant amyloid precursor protein and presenilin 1 transgenes , 1998, Nature Medicine.
[48] K. Duff,et al. Quantitative histological analysis of amyloid deposition in Alzheimer’s double transgenic mouse brain , 2000, Neuroscience.
[49] J. Hardy,et al. Increased amyloid-β42(43) in brains of mice expressing mutant presenilin 1 , 1996, Nature.
[50] O. Arancio,et al. Usefulness of Behavioral and Electrophysiological Studies in Transgenic Models of Alzheimer's Disease , 2003, Neurochemical Research.
[51] L. Mucke,et al. Alzheimer-type neuropathology in transgenic mice overexpressing V717F β-amyloid precursor protein , 1995, Nature.
[52] T. Bliss,et al. Impaired synaptic plasticity and learning in aged amyloid precursor protein transgenic mice , 1999, Nature Neuroscience.
[53] D. Diamond,et al. Progressive, age-related behavioral impairments in transgenic mice carrying both mutant amyloid precursor protein and presenilin-1 transgenes , 2001, Brain Research.
[54] H. Meziane,et al. Behavioral disturbances in transgenic mice overexpressing the V717F beta-amyloid precursor protein. , 1999, Behavioral neuroscience.
[55] B. Hyman,et al. APPSW Transgenic Mice Develop Age‐related Aβ Deposits and Neuropil Abnormalities, but no Neuronal Loss in CA1 , 1997, Journal of neuropathology and experimental neurology.
[56] B. Hyman,et al. Microglial response to amyloid plaques in APPsw transgenic mice. , 1998, The American journal of pathology.
[57] D. Borchelt,et al. Accelerated Amyloid Deposition in the Brains of Transgenic Mice Coexpressing Mutant Presenilin 1 and Amyloid Precursor Proteins , 1997, Neuron.
[58] T. Nabeshima,et al. Impairments of long-term potentiation in hippocampal slices of beta-amyloid-infused rats. , 1999, European journal of pharmacology.
[59] D. Linden,et al. Synaptic Transmission and Hippocampal Long-Term Potentiation in Transgenic Mice Expressing FAD-Linked Presenilin 1 , 1999, Neurobiology of Disease.
[60] W. K. Cullen,et al. Block of LTP in rat hippocampus in vivo by beta-amyloid precursor protein fragments. , 1997, Neuroreport.
[61] H. Tanila,et al. Hippocampal Aβ42 Levels Correlate with Spatial Memory Deficit in APP and PS1 Double Transgenic Mice , 2002, Neurobiology of Disease.
[62] George A. Carlson,et al. The Relationship between Aβ and Memory in the Tg2576 Mouse Model of Alzheimer's Disease , 2002, The Journal of Neuroscience.
[63] Xin Wu,et al. Immunization reverses memory deficits without reducing brain Aβ burden in Alzheimer's disease model , 2002, Nature Neuroscience.
[64] B. Yee,et al. Behavioral and neurochemical characterization of transgenic mice carrying the human presenilin-1 gene with or without the leucine-to-proline mutation at codon 235 , 2003, Experimental Neurology.
[65] R. Malinow,et al. Enhanced Synaptic Potentiation in Transgenic Mice Expressing presenilin 1 Familial Alzheimer's Disease Mutation Is Normalized with a Benzodiazepine , 2000, Neurobiology of Disease.
[66] W. K. Cullen,et al. Block of LTP in rat hippocampus in vivo by β‐amyloid precursor protein fragments , 1997 .
[67] S. Younkin,et al. The relationship between Abeta and memory in the Tg2576 mouse model of Alzheimer's disease. , 2002, The Journal of neuroscience : the official journal of the Society for Neuroscience.
[68] T. Bliss,et al. A synaptic model of memory: long-term potentiation in the hippocampus , 1993, Nature.
[69] W. K. Cullen,et al. Naturally secreted oligomers of amyloid β protein potently inhibit hippocampal long-term potentiation in vivo , 2002, Nature.
[70] K. Duff,et al. Behavioral Changes in Transgenic Mice Expressing Both Amyloid Precursor Protein and Presenilin-1 Mutations: Lack of Association with Amyloid Deposits , 1999, Behavior genetics.
[71] T. Iwatsubo,et al. Visualization of Aβ42(43) and Aβ40 in senile plaques with end-specific Aβ monoclonals: Evidence that an initially deposited species is Aβ42(43) , 1994, Neuron.
[72] O. Arancio,et al. Receptor protein tyrosine phosphatase α is essential for hippocampal neuronal migration and long‐term potentiation , 2003 .
[73] T. Priestley,et al. Long-Term Potentiation Is Increased in the CA1 Area of the Hippocampus of APPswe/ind CRND8 Mice , 2002, Neurobiology of Disease.
[74] C. Stevens,et al. Presynaptic mechanism for long-term potentiation in the hippocampus , 1990, Nature.
[75] B. Sommer,et al. Neuron loss in APP transgenic mice , 1998, Nature.